Consequently, targeting GRM8 and similar regulatory genes may represent a viable strategy for reactivating sensitivity to the tumor‐suppressive and pro‐senescent effects of the TGF‐β/Smad3 axis. This evidence concerns the gene SMAD3 and neoplasm.